Xencor (NASDAQ:XNCR – Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.83, FiscalAI reports. The company had revenue of $116.52 million during the quarter, compared to analysts’ expectations of $63.00 million. Xencor had a negative return on equity of 21.37% and a negative net margin of 58.79%. Xencor’s revenue was up 453.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.08) EPS.
Xencor Stock Performance
Shares of NASDAQ:XNCR opened at $34.05 on Friday. Xencor has a 12 month low of $10.38 and a 12 month high of $35.81. The company’s fifty day simple moving average is $26.04 and its 200 day simple moving average is $17.34.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on XNCR shares. Wells Fargo & Company boosted their price objective on shares of Xencor from $30.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, October 27th. Cantor Fitzgerald started coverage on shares of Xencor in a research report on Thursday. They set an “overweight” rating and a $70.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on shares of Xencor from $14.00 to $21.00 and gave the stock a “neutral” rating in a research report on Thursday, September 3rd. Wall Street Zen raised shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Xencor has an average rating of “Moderate Buy” and an average price target of $42.22.
View Our Latest Analysis on XNCR
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.
Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.
Read More
- Five stocks we like better than Xencor
- These 3 Underperforming Stocks Are Seeing Notable CEO Insider Trades
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
